logo-loader
RNS
viewAvacta Group PLC

Avacta Group PLC - Posting of Annual Report and Notice of AGM

RNS Number : 1313O
Avacta Group PLC
28 May 2020
 

 

 

 

 

28 May 2020

Avacta Group plc

("Avacta" or "the Group" or "the Company")

 

Posting of Annual Report and Notice of AGM

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its Annual Report and Accounts for the period ended 31 December 2019 and the Notice of the 2020 Annual General Meeting are now available on the Company's website www.avacta.com.

 

Copies of the Annual Report and Accounts and the Notice of AGM have been posted to shareholders who have elected to receive them in paper form.

 

The Annual General Meeting will be held on Monday, 22 June 2020 at 2.00 p.m. at the offices of Walker Morris LLP at 33 Wellington Street, Leeds LS1 4DL. 

 

In the light of the COVID-19 pandemic and current Government advice on public gatherings, shareholders are strongly urged to appoint the Chairman of the Meeting as their proxy as attendance in person is not advised and members and their proxies may be refused entry if circumstances permit or require.

 

- Ends -

 

For further information from Avacta Group plc, please contact:
 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel:  +44 (0) 844 414 0452

www.avacta.com

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Giles Rolls - Corporate Finance

Tim Redfern - ECM

Tel:  +44 (0) 207 220 0500

www.finncap.com


Zeus Capital Limited (Joint Broker)

John Goold / Rupert Woolfenden - Corporate Broking


Tel: +44 (0)203 829 5000

www.zeuscapital.co.uk

 


Yellow Jersey PR (Financial Media and IR)

Sarah Hollins

Henry Wilkinson

 


Tel: +44 (0)203 004 9512

Tel: +44 (0)7764 947 137

Tel: +44 (0)7951 402 336

[email protected]


Zyme Communications (Trade and Regional Media)

Katie Odgaard


Tel: +44 (0)7787 502 947

[email protected] 

 


About Avacta Group plc - https://www.avacta.com

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer® biotherapeutics and pre|CISION™ tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company's therapeutics development activities are based in Cambridge, UK.

 

The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.

 

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn.  Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal's immune response, to generate new antibodies; poor specificity in many cases; large size and cost. 

 

Avacta's pre|CISION targeted chemotherapy platform, releases active chemotherapy only in the tumour, thereby limiting systemic exposure and damage to healthy tissues, and thereby improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. 

 

By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first drug, a pre|CISION targeted form of the standard-of-care Doxorubicin, into the clinic in later in 2020 or early 2021.

 

Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., a deal with LG Chem worth up to $310m, a partnership with ADC Therapeutics to develop Affimer drug conjugates and has established a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators. Avacta actively seeks to license its proprietary platforms in a range of therapeutic areas.

 

Avacta diagnostics business unit works with partners world-wide to develop Affimers for evaluation by those third parties with the objective of establishing royalty bearing license deals. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCPPUWUAUPUGQM

Quick facts: Avacta Group PLC

Price: 119.5

Market: AIM
Market Cap: £297.31 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19